Free tool
FAERS Monitor: Urocit-K
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019071 or its brand name (Urocit-K, Potassium Citrate). Reports on generic versions are filed under their own applications.
Reports
5,569
Serious
3,307
59% of reports
Hospitalization
1,734
Death reported
320
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective462
- fatigue378
- nausea340
- diarrhoea339
- pain309
- nephrolithiasis279
- off label use271
- dizziness248
- dyspnoea229
- headache217
- fall207
- vomiting186
- asthenia164
- pneumonia161
- arthralgia156
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 16 |
| 2005 | 17 |
| 2006 | 26 |
| 2007 | 34 |
| 2008 | 35 |
| 2009 | 57 |
| 2010 | 78 |
| 2011 | 104 |
| 2012 | 112 |
| 2013 | 123 |
| 2014 | 145 |
| 2015 | 290 |
| 2016 | 365 |
| 2017 | 326 |
| 2018 | 374 |
| 2019 | 373 |
| 2020 | 409 |
| 2021 | 449 |
| 2022 | 516 |
| 2023 | 450 |
| 2024 | 446 |
| 2025 | 484 |
| 2026 | 340 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,590 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nephrolithiasisSignal | 279 | 23.1 | 20.6 | 5,856 |
| fallSignal | 207 | 2.3 | 2.1 | 162 |
| diarrhoea | 339 | 2.0 | 1.8 | 170 |
| pain | 309 | 1.9 | 1.7 | 135 |
| pneumonia | 161 | 1.9 | 1.6 | 66 |
| dizziness | 248 | 1.9 | 1.7 | 103 |
| fatigue | 378 | 1.8 | 1.7 | 148 |
| asthenia | 164 | 1.6 | 1.4 | 42 |
| nausea | 340 | 1.6 | 1.5 | 84 |
| dyspnoea | 229 | 1.5 | 1.3 | 42 |
| vomiting | 186 | 1.5 | 1.3 | 31 |
| arthralgia | 156 | 1.4 | 1.2 | 19 |
| drug ineffective | 462 | 1.3 | 1.2 | 39 |
| headache | 217 | 1.3 | 1.1 | 16 |
| off label use | 271 | 1.2 | 1.0 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.